RS50571B - Postupak za proizvodnju derivata (3-okso-2,3-dihidro-1h-izoindol-1-1l)-acetil-gvanidina - Google Patents

Postupak za proizvodnju derivata (3-okso-2,3-dihidro-1h-izoindol-1-1l)-acetil-gvanidina

Info

Publication number
RS50571B
RS50571B RSP-2008/0311A RSP20080311A RS50571B RS 50571 B RS50571 B RS 50571B RS P20080311 A RSP20080311 A RS P20080311A RS 50571 B RS50571 B RS 50571B
Authority
RS
Serbia
Prior art keywords
formula
compound
isoindol
dihydro
oxo
Prior art date
Application number
RSP-2008/0311A
Other languages
English (en)
Inventor
Gerrit Schubert
Joerg Rieke-Zapp
Johannes Keil
Heinz-Werner Kleemann
Reda Hanna
Bao-Guo Huang
Xiao-Dong Wu
Yves Gouraud
Original Assignee
Sanofi-Aventis Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschland Gmbh. filed Critical Sanofi-Aventis Deutschland Gmbh.
Publication of RS50571B publication Critical patent/RS50571B/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Postupak za proizvodnju jedinjenja formule Iu kojoj označavajuRl i R2 nezavisno jedan od drugog vodonik, F, Cl, trifluormetoksi, 2,2,2-trifluoretoksi, trifluormetil, 2,2,2-trifluoretil ili alkil sa 1, 2, 3 ili 4 C-atoma;R3 alk-R4 ili trifluorometil;alk alkil sa 1, 2, 3 ili 4 C-atoma;R4 vodonik, trifluormetil ili cikloalkil sa 3, 4, 5, 6 ili 7 C-atoma;kao i njihove soli; naznačen time, što jea) amid formule IV formiliran i zatim cikliziran ujedinjenje formule VI,b) jedinjenje formule VI sa jednim alkoksikarbonilmetilentrifenilfosforanom, sa jednim 1-alkoksi-l-trimetilsiloksietilenom ili sa jednim trialkilfosfono-acetatom prevede u jedinjenje formule VII, ic) jedinjenje formule VII sa gvanidinom prevede u jedinjenje formule I,pri čemu ujedinjenjima formule IV, VI i VII Rl do R3 su definisani kao i u formuli I i R5 je alkoksi sa 1, 2, 3 ili 4 C-atoma; kao i njihove soli. Prijava sadrži još 22 patentna zahteva.
RSP-2008/0311A 2003-12-02 2004-11-19 Postupak za proizvodnju derivata (3-okso-2,3-dihidro-1h-izoindol-1-1l)-acetil-gvanidina RS50571B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10356717A DE10356717A1 (de) 2003-12-02 2003-12-02 Verfahren zur Herstellung von (3-Oxo-2,3-dihydro-1H-isoindol-1-yl)-acetylguanidin-Derivaten
PCT/EP2004/013153 WO2005054195A1 (de) 2003-12-02 2004-11-19 VERFAHREN ZUR HERSTELLUNG VON (3-OXO-2,3-DIHYDRO-1H-ISOINDOL-1-Yl)-ACETYLGUANIDIN-DERIVATEN

Publications (1)

Publication Number Publication Date
RS50571B true RS50571B (sr) 2010-05-07

Family

ID=34638338

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0311A RS50571B (sr) 2003-12-02 2004-11-19 Postupak za proizvodnju derivata (3-okso-2,3-dihidro-1h-izoindol-1-1l)-acetil-gvanidina

Country Status (38)

Country Link
EP (1) EP1692105B1 (sr)
JP (1) JP4809774B2 (sr)
KR (1) KR101202604B1 (sr)
CN (1) CN100526297C (sr)
AR (1) AR046733A1 (sr)
AT (1) ATE395334T1 (sr)
AU (1) AU2004295056B2 (sr)
BR (1) BRPI0417147A (sr)
CA (1) CA2548020C (sr)
CR (1) CR8376A (sr)
CY (1) CY1108187T1 (sr)
DE (2) DE10356717A1 (sr)
DK (1) DK1692105T3 (sr)
EC (1) ECSP066597A (sr)
EG (1) EG25498A (sr)
ES (1) ES2304634T3 (sr)
HK (1) HK1097525A1 (sr)
HR (1) HRP20080253T3 (sr)
IL (1) IL175834A (sr)
JO (1) JO2498B1 (sr)
MA (1) MA28220A1 (sr)
MY (1) MY136467A (sr)
NO (1) NO20063058L (sr)
NZ (1) NZ547625A (sr)
OA (1) OA13293A (sr)
PA (1) PA8618701A1 (sr)
PE (1) PE20051037A1 (sr)
PL (1) PL1692105T3 (sr)
PT (1) PT1692105E (sr)
RS (1) RS50571B (sr)
RU (1) RU2397159C2 (sr)
SI (1) SI1692105T1 (sr)
TN (1) TNSN06167A1 (sr)
TW (1) TWI334348B (sr)
UA (1) UA83883C2 (sr)
UY (1) UY28648A1 (sr)
WO (1) WO2005054195A1 (sr)
ZA (1) ZA200603338B (sr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200812962A (en) * 2006-07-12 2008-03-16 Astrazeneca Ab New compounds I/418
CN102007138B (zh) * 2008-04-16 2014-05-21 橘生药品工业株式会社 吡唑衍生物的半富马酸盐
RU2518740C1 (ru) * 2013-03-22 2014-06-10 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" СРЕДСТВО, ИНГИБИРУЮЩЕЕ Na+/H+-ОБМЕН, И ДИГИДРОХЛОРИД 2-(3,4-МЕТИЛЕНДИОКСИФЕНИЛ)-9-МОРФОЛИНОЭТИЛИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА
CN107778238B (zh) * 2016-08-29 2022-07-22 中山大学 一种3,4-二氢异喹啉-1-酮的合成新方法
CN107286074B (zh) * 2017-08-16 2019-08-20 厦门华厦学院 3-羟基异吲哚-1-酮衍生物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946842A (en) * 1985-07-05 1990-08-07 Smith Kline & French Laboratories Limited Novel guanidino pyridazinones as cardiac stimulants
DE19737224A1 (de) * 1997-08-27 1999-03-18 Hoechst Marion Roussel De Gmbh Pharmazeutisches Kombinationspräparat aus einem Inhibitor des Natrium-Wasserstoff-Austauschers und einem Arzneimittel zur Behandlung von Herz-Kreislauferkrankungen
DE19832429A1 (de) * 1998-07-18 2000-01-20 Hoechst Marion Roussel De Gmbh Imidazolderivate mit Biphenylsulfonylsubstitution, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PT1385823E (pt) 2001-04-09 2007-01-31 Novartis Vaccines & Diagnostic Compostos de guanidino como agonistas do receptor de melanocortina-4 (r-mc4)
FR2840302B1 (fr) * 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Also Published As

Publication number Publication date
AU2004295056A1 (en) 2005-06-16
NZ547625A (en) 2010-01-29
HK1097525A1 (en) 2007-06-29
SI1692105T1 (sl) 2008-08-31
MA28220A1 (fr) 2006-10-02
OA13293A (en) 2007-01-31
KR101202604B1 (ko) 2012-11-19
UY28648A1 (es) 2005-06-30
CR8376A (es) 2007-12-04
PE20051037A1 (es) 2005-12-29
NO20063058L (no) 2006-06-30
EP1692105B1 (de) 2008-05-14
CA2548020C (en) 2013-01-08
DE10356717A1 (de) 2005-07-07
UA83883C2 (en) 2008-08-26
JP4809774B2 (ja) 2011-11-09
WO2005054195A1 (de) 2005-06-16
CN1886374A (zh) 2006-12-27
PL1692105T3 (pl) 2008-09-30
ECSP066597A (es) 2006-10-25
KR20060111558A (ko) 2006-10-27
CA2548020A1 (en) 2005-06-16
EG25498A (en) 2012-01-22
BRPI0417147A (pt) 2007-03-06
IL175834A0 (en) 2006-10-05
TWI334348B (en) 2010-12-11
CY1108187T1 (el) 2014-02-12
DK1692105T3 (da) 2008-08-25
CN100526297C (zh) 2009-08-12
RU2006123410A (ru) 2008-01-10
ZA200603338B (en) 2007-06-27
DE502004007177D1 (de) 2008-06-26
ES2304634T3 (es) 2008-10-16
AU2004295056B2 (en) 2011-04-14
TW200526207A (en) 2005-08-16
RU2397159C2 (ru) 2010-08-20
PT1692105E (pt) 2008-07-04
JP2007516243A (ja) 2007-06-21
JO2498B1 (en) 2009-10-05
TNSN06167A1 (en) 2007-11-15
IL175834A (en) 2010-12-30
ATE395334T1 (de) 2008-05-15
PA8618701A1 (es) 2006-07-03
MY136467A (en) 2008-10-31
AR046733A1 (es) 2005-12-21
EP1692105A1 (de) 2006-08-23
HRP20080253T3 (en) 2008-09-30

Similar Documents

Publication Publication Date Title
HRP20090533T1 (en) Indolyl derivatives as liver-x-receptor modulators
EP1595870A4 (en) PROCESS FOR PRODUCING A PHENYLALANINE DERIVATIVE HAVING A QUINAZOLINEDIONE SKELETON AND INTERMEDIATE THEREOF
HRP20090151T3 (en) Indozolone derivatives as 11b-hsd1 inhibitors
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
MEP22008A (en) Derivatives of n-[heteroaryl(piperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
MEP51408A (en) Selected cgrp antagonists, method for production and use thereof as medicament
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
ME00108B (me) DE RIVATI DIOKSAN-2-ALKILKARBAMATA, POSTUPAK ZA NJIHOVO DOBIJANJ E l PRIMENA ISTIH U TERAPEUTICIMA
WO2008051533A3 (en) Benzimidazole compounds
MX2010001774A (es) Pirrolidin aril-eteres como antagonistas de receptores de nk3.
ATE491704T1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
AR035111A1 (es) Procedimiento para preparar un compuesto de pirimidinona
JOP20190239A1 (ar) مركبات مثبطة لـ vmat2 وتركيبات منها
MX2009006650A (es) Pirimidinas substituidas que contienen una porcion heteroarilamida o heteroarilfenilo.
ATE495158T1 (de) Substituierte tetrahydroisochinoline als mmp- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
HUP0402244A2 (hu) Heterociklusos glicinamid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HRP20080253T3 (en) Method for producing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives
TW200619201A (en) Process for the preparation of pyrazoles
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren
NO20023480L (no) Fremgangsmåte for rensing av avgass-strömmer
AR056805A1 (es) Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
JO2433B1 (en) Preparation of heterocyclic lindane landscapes
HUP0200808A2 (hu) Eljárás a piperazingyűrű kialakítására és új piperazinszármazékok